EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial

Chao Jiang iD, Zixu Zhao iD, Zejun Yang iD, Yiping Wang iD, Yang Xu, Hui Xu, Hang Guo iD, Chi Wang iD, Liu He, Shijun Xia iD, Xiangyi Kong, Wenli Dai und 16 weitere

Circulation · 03.02.2026 · 153 (5) · 297-306

DOI: 10.1161/circulationaha.125.077447 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 03.02.2026. Verfasst von Chao Jiang und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BMHB | Capital Health Research and Development of Special Fund, Beijing Municipal Health Commission, Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Observational studies have suggested that SGLT2 (sodium-glucose cotransporter 2) inhibitors are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation in patients with AF with concomitant diabetes, heart failure, or chronic kidney disease. However, no randomized trial to date has tested whether SGLT2 inhibitors reduce AF recurrence after ablation in patients without established indications. We therefore investigated the effect of dapagliflozin on prevention of early recurrence of AF after catheter ablation in patients without current indications for SGLT2 inhibitors. METHODS: The DARE-AF trial (Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation) was a prospective, open-label, parallel-assignment randomized controlled trial that enrolled 200 patients with persistent AF between July 2024 and March 2025, scheduled to undergo a first catheter ablation procedure and without established indications for dapagliflozin (diabetes, heart failure, or chronic kidney disease). Patients were randomly assigned at a 1:1 ratio to dapagliflozin (10 mg once daily for 3 months after the ablation) or control. The primary end point was AF burden at 3 months after ablation, assessed by 7-day single-lead ECG patches. Secondary outcomes included time to events, quality of life, and improvement of atrial remodeling. RESULTS: A total of 200 patients (mean age 58.5 years, 19.5% women, 29.0% with persistent AF ≥1 year) were randomized, and 198 patients (98 in the dapagliflozin group, 100 in the control group) were included in the primary analysis. Three months after ablation, the difference in AF burden was insignificant between the dapagliflozin group and the control group (7.5±23.6% versus 8.1±25.5%; P =0.48). Atrial arrhythmia recurrence occurred in 29 patients (29.6%) in the dapagliflozin group and 28 patients (28.0%) in the control group (hazard ratio, 1.11 [95% CI, 0.66–1.86]; P =0.70). No significant between-group differences were observed in changes in quality of life or left atrial diameter. CONCLUSIONS: Three-month treatment with dapagliflozin did not reduce the early recurrence of arrhythmia after catheter ablation in patients with persistent AF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06433479.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsHumansFemaleMaleMiddle AgedAgedRecurrenceProspective StudiesTreatment OutcomeQuality of Life

Stichwörter der Autor:innen

SGLT2 inhibitoratrial fibrillationcatheter ablationrecurrence

Substanzen

Benzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China (Chao Jiang, Z.Z., Z.Y., Y.W., Y.X., H.X., H.G., L.H., S.X., X…
  • Heart Health Research Center, Beijing, China (Chao Jiang, X.D.).
  • College of Public Health, University of Iowa, lowa City, IA (C.W.).
  • Department of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.C.Z.).
  • Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada (L.M.).

ORCID-Profile: Chao Jiang, Zixu Zhao, Zejun Yang, Yiping Wang, Hang Guo, Chi Wang, Shijun Xia, Junmeng Zhang, Song Zuo, Nian Liu, Songnan Li, Ribo Tang, Caihua Sang, Paul C Zei, Deyong Long, Xin Du, Jianzeng Dong, Laurent Macle, Changsheng Ma

Förderung

  • BMHB | Capital Health Research and Development of Special Fund
  • Beijing Municipal Health Commission
  • Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
  • Ministry of Science and Technology of the People's Republic of China
  • National Nature Science Foundation of China

Zitieren

APA

Jiang, C., Zhao, Z., Yang, Z., Wang, Y., Xu, Y., Xu, H., Guo, H., Wang, C., He, L., Xia, S., Kong, X., Dai, W., Zhang, J., Zuo, S., Liu, X., Guo, X., Liu, N., Li, S., Zhou, N., …, & Ma, C. (2026). Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. Circulation, 153(5), 297-306. https://doi.org/10.1161/circulationaha.125.077447

Vancouver

Jiang C, Zhao Z, Yang Z, Wang Y, Xu Y, Xu H, et al. Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. Circulation. 2026;153(5):297-306. doi:10.1161/circulationaha.125.077447

BibTeX
@article{Jiang2026,
  author = {Jiang, Chao and Zhao, Zixu and Yang, Zejun and Wang, Yiping and Xu, Yang and Xu, Hui and Guo, Hang and Wang, Chi and He, Liu and Xia, Shijun and Kong, Xiangyi and Dai, Wenli and Zhang, Junmeng and Zuo, Song and Liu, Xiaoxia and Guo, Xueyuan and Liu, Nian and Li, Songnan and Zhou, Ning and Jiang, Chenxi and Tang, Ribo and Sang, Caihua and Zei, Paul C and Long, Deyong and Du, Xin and Dong, Jianzeng and Macle, Laurent and Ma, Changsheng},
  title = {Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial},
  journal = {Circulation},
  year = {2026},
  volume = {153},
  number = {5},
  pages = {297--306},
  doi = {10.1161/circulationaha.125.077447}
}
Kostenlos starten →